UK Markets closed

MDxHealth SA (0O8G.L)

LSE - LSE Delayed price. Currency in EUR
Add to watchlist
0.8290+0.0050 (+0.61%)
At close: 08:34AM BST
Full screen
Previous close0.8240
Open0.8290
Bid0.0000 x 0
Ask0.0000 x 0
Day's range0.8290 - 0.8290
52-week range0.8290 - 0.8290
Volume200
Avg. volumeN/A
Market cap45.836M
Beta (5Y monthly)1.37
PE ratio (TTM)N/A
EPS (TTM)-0.2490
Earnings dateN/A
Forward dividend & yieldN/A (N/A)
Ex-dividend dateN/A
1y target estN/A
  • Globe Newswire

    MDxHealth Announces Results of its Annual and Extraordinary General Shareholders’ Meetings and Resignation of Director

    NEWS RELEASE - REGULATED INFORMATION 25 May 2022, 4:00 p.m. EDT / 22:00 CET MDxHealth Announces Results of its Annual and Extraordinary General Shareholders’ Meetings and Resignation of Director IRVINE, CA, and HERSTAL, BELGIUM – 25 May 2022 – MDxHealth SA (Nasdaq and Euronext Brussels: MDXH) ("MDxHealth" or the "Company"), a commercial-stage precision diagnostics company, today held its ordinary annual general shareholders' meeting ("AGM") and an extraordinary general shareholders' meeting ("EG

  • Globe Newswire

    Palmetto GBA’s MolDX Issues Foundational LCD Covering the Indication for SelectMDx for Prostate Cancer

    NEWS RELEASE - REGULATED INFORMATIONMay 19, 2022, 4:00PM EDT / 22:00 CET Palmetto GBA’s MolDX Issues Foundational LCD Covering the Indication for SelectMDx® for Prostate Cancer IRVINE, CA, and HERSTAL, BELGIUM – May 19, 2022 – – MDxHealth SA (NASDAQ/Euronext: MDXH), a commercial stage precision diagnostics company, announces that Palmetto GBA, a Medicare Administrative Contractor (MAC) that assesses molecular diagnostic technologies under its MolDX program, has finalized a foundational Local Cov

  • Globe Newswire

    MDxHealth Reports Q1-2022 Results

    NEWS RELEASE - REGULATED INFORMATION27 APRIL 2022, 4:00PM EDT / 22:00 CET MDxHealth Reports Q1-2022 Results IRVINE, CA, and HERSTAL, BELGIUM – April 27, 2022 – MDxHealth SA (NASDAQ/Euronext: MDXH), a commercial-stage precision diagnostics company, today announced its financial results for the first quarter ended March 31, 2022. Michael McGarrity, CEO of MDxHealth, commented: “We are excited to report greater than 20% revenue growth for Q1 as well as the resumption of year-over-year unit growth f